基础医学与临床 ›› 2023, Vol. 43 ›› Issue (2): 301-305.doi: 10.16352/j.issn.1001-6325.2023.02.301

• 短篇综述 • 上一篇    下一篇

RhoGTP酶活化蛋白在上皮细胞间质转化中作用的研究进展

徐倩, 段华*, 甘露, 刘麒薇   

  1. 首都医科大学附属北京妇产医院 妇科微创中心,北京 100006
  • 收稿日期:2021-07-28 修回日期:2022-01-07 出版日期:2023-02-05 发布日期:2023-02-02
  • 通讯作者: *duanhua@ccmu.edu.cn
  • 基金资助:
    国家自然科学基金青年科学基金(81801403);首都医科大学附属北京妇产医院中青年学科骨干培养专项(FCYY201823)

Research progress of RhoGTPase activating protein in epithelial-mesenchymal transition

XU Qian, DUAN Hua*, GAN Lu, LIU Qiwei   

  1. Department of Gynecology Minimally Invasive Center, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China
  • Received:2021-07-28 Revised:2022-01-07 Online:2023-02-05 Published:2023-02-02
  • Contact: *duanhua@ccmu.edu.cn

摘要: 上皮细胞间质转化(EMT)是指上皮细胞在形态上发生向间(充)质细胞表型的转变,并获得迁移能力,其在肿瘤细胞侵袭及纤维化疾病的形成中起着重要作用。RhoGTP酶活化蛋白(RhoGAP)可以通过参与调控细胞表面受体同肌动蛋白细胞骨架的信号传导,影响EMT相关的肿瘤转移及组织纤维化转归,为后续寻找抗肿瘤及抗纤维化的治疗靶点提供分子诊疗思路。

关键词: RhoGTP酶活化蛋白, 上皮细胞间质转化, 肌动蛋白细胞骨架, 肿瘤转移, 纤维化疾病

Abstract: Epithelial-mesenchymal transition (EMT) is a process by which epithelial cells undergo morphological changes to gain a mesenchymal cell phenotype and migratory properties. As a class of negative regulators of RhoGTPases, RhoGTPase activating proteins(RhoGAP) can bridge between cell surface receptors and cellular actin cytoskeleton during EMT procedure, which may influence cancer cell transition and outcome of fibrotic diseases and may help search for anti-tumor and anti-fibrotic managements.

Key words: RhoGTPase activating protein, epithelial-mesenchymal transition, actin cytoskeleton, metastasis, fibrotic diseases

中图分类号: